Table 3.
Sensitivity analyses for the association of colistin with AKI at the end of follow-up
| Sensitivity Analysis | IRR (95% CI) |
|---|---|
| Exclude course <72 h in durationa | 3.2 (1.9 to 5.4) |
| 5-d Postexposure follow-upb | 2.9 (1.9 to 4.4) |
| Exclude patients with pre-exposure AKIc | 5.7 (3.1 to 10.4) |
| Propensity score stratificationd | 2.9 (2.3 to 3.9) |
| Exclude patients with CKDe | 3.3 (1.9 to 6.0) |
| KDIGO stage 2 or higher AKIf | 3.7 (2.1 to 6.7) |
IRR, incidence rate ratio; 95% CI, 95% confidence interval; KDIGO, Kidney Disease Improving Global Outcomes.
a
Analysis included 117 matched pairs.
b
Analysis included 150 matched pairs.
c
Analysis included 101 matched pairs.
d
Stratified across propensity score quintile.
e
Analysis included 100 matched pairs.
f
AKI definition revised to include only KDIGO stage 2 or higher AKI events.